Please login to create your UC TechAlerts.
Request a new password for
Required
Find technologies available for licensing from UC Riverside.
No technologies match these criteria. Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above
Steerable Laser Interstitial Thermotherapy Robot
Brief description not available
Shape Memory Alloy Enabled Robotic Modular Mass Debrider
Novel AMPK Inhibitors and Activators
Professor Kevin Kou and colleagues from the University of California, Riverside and the City of Hope National Medical Center have developed a chemical synthetic strategy that allows for the efficient generation of a diverse library of oxyberberine derivatives. This technology is advantageous because the family of protoberberine molecules, the best known being berberine, is generally considered non-toxic. As such, protoberberine derivatives are likely to elicit a better safety profile compared to existing AMPK inhibitors that are highly toxic and be developed to treat a range of diseases. Fig 1: Four of the UCR novel AMPK inhibitors resulting from the UCR synthesis strategy.
Creatine Microparticles for Highly Effective Intranasal Delivery
Professor Xiaoping Hu’s lab at the University of California, Riverside has developed a novel method that allows creatine to bypass the BBB and directly reach the brain. The technology works by delivering creatine intranasally using microparticles. These creatine particles have shown to not exhibit cytotoxicity, are highly stable, and are not disruptive to cell barriers. This technology is advantageous over traditional creatine monohydrate and anhydrous creatine because the smaller particle size ensures even distribution and greater permeability across the BBB.
Nanoparticles With Enhanced Fluorescence for Medical Imaging and Research Purposes
Professor Bahman Anvari and colleagues from the University of California, Riverside and the University of Maryland have developed nanoparticle systems with greater fluorescence emission when compared to known dyes. These nanoparticles incorporate dual near infrared fluorescence (NIR) and magnetic resonance (MR) dyes for improved fluorescence. The nanoparticles encapsulate brominated carbocyanine dyes with MR qualities and ICG with NIR properties. This technology is advantageous because these nanoparticles containing these dyes exhibit greater fluorescence emission when compared to the individual dyes. This presents a promising dual-mode platform with high optical sensitivity and clinical diagnostic and research applications.
Novel Proteasome Inhibitors
This technology provides methods for synthesizing a group of naturally occurring compounds, syrbactins, and their derivatives, being of significant commercial value due to the ability of some of the members to inhibit proteasomal activity. TIR-199, for example, is one of the most potent proteasome inhibitors synthesized so far. The efficacy and efficiency of this novel drug candidate in inducing tumor cell death in multiple myeloma, neuroblastoma, and other types of cancer (e.g. kidney, colon, melanoma, ovarian) has been demonstrated using in vitro systems, cell lines, and animal models (reported for the first time for a syrbactin compound). TIR-199 drug candidate is ready for further pre-clinical and eventually clinical studies.
High-Fidelity Cas13a Variants
Professor Giulia Palermo and colleagues from the University of California, Riverside and the University of Rochester have developed high-fidelity Cas13a variants with increased sensitivity for base pair mismatches.The activation of these Cas13a variants can be inhibited with a single mismatch between guide-RNA and target-RNA, a property that can be used for the detection of SNPs associated with diseases or specific genotypic sequences.
Handheld Device For Quick DNA Extraction
Professor Hideaki Tsutsui and colleagues from the University of California, Riverside have developed a portable handheld device for nucleic acid extraction. With its high-speed motor, knurled lysis chamber for rapid sample lysis, and quick nucleic acid extraction using paper disks, this device can yield ready-to-use extracts in just 12 minutes, significantly reducing the time required for sample preparation. This technology is advantageous over current methods as it can be expedited without the need for cumbersome specimen collection, packaging, and submission, shortening the turnaround time.
The Poor Man’s Trough: A Bench Top Motor Free Method To 3D Langmuir-Blodgett Films
Aerobic Biotransformation and Defluorination of ether PFAS
Substantial defluorination of chlorinated PFCAs
Isolette-Msa, The Intelligent Isolette Through Integration Of Artificial Intelligence (Ai) Drive Multi-Sensors
A General Magnetic Assembly Approach To Chiral Superstructures At All Scales
Daily Move© - Infant Body Position Classification
Prof. John Franchak and his team have developed a prototype system that accurately classifies an infant's body position.
Dual Mode Velocity Selective Arterial Spin Labeling (Vsasl)
Smart Insulin Leak Detector
Methods Of Synthesis Of Quantum Composites And Applications For Energy Storage And Reflective Coatings
Novel Cell Penetrating Peptide for Drug Delivery
Professor Min Xue and his lab at the University of California, Riverside have developed a novel hydrophilic endocytosis-promoting peptide (EPP6) rich in hydroxyl groups with no positive charge that may be used for drug delivery purposes. This peptide is non-toxic and has been shown to transport a wide array of small-molecule cargos into a diverse panel of cells. It enables oral administration and absorption through the intestinal lining, and crosses the BBB in vivo. UCR EPP6 is advantageous over existing technologies since it is nontoxic, efficiently enables oral absorption and transport across the BBB. Fig 1: A) Structure of the UCR EPP. B) Confocal images showing that EPP6 was able to transport different cargo molecules into the cells. C) Orally administered EPP6 is absorbed by the intestines, entering the blood circulation and reaching the brain.
New Device to Test for Pulmonary Function for 21st Century Care
Prof. Mona Eskandari, whose research is known for seminal strides in experimental characterization and computational modeling of lung structural mechanics using novel techniques developed in her lab, has discovered a new method for measuring pulmonary function. It works by analyzing the change in temporal pressure while a patient is holding their breath. The measurement device is simple, comfortable and error-free for the patient to self-administer. Algorithms are used to transform the detailed lung data collection into actionable metrics for early detection capabilities for medical intervention and prevention. The discovery could provide more accessible, detailed, timely, and actionable data on lung function compared to conventional and currently used methods. Fig 1: The medical device prototype being tested in the laboratory Fig 2: Preliminary data exhibiting detectable differences between several healthy and diseased mice lungs when utilizing the proposed new pulmonary function method
Functionalized Sila-Adamantane
Novel Genetic Switch for Inducing Gene Expression
Prof. Sean Cutler and colleagues at the University of California, Riverside have engineered a system and methods to induce gene expression in plants and organisms, including mammals, using the chemical compound mandipropamid. Using the PYR/PYL/HAB1 promoter system, the PYR1/HAB1 system is reprogrammed to be activiated with mandipropamid. When the PYR1/HAB1 system dimerizes through chemical induced dimerization (CID) with mandipropamid, the system functions as a control switch for gene expression. This technology has been demonstrated to advantageously accelerate citrus breeding. It may be applied to improve CAR T-cell therapy and agricultural crops. Fig 1: UCR’s PYR1/HAB1 system is programmed through chemical induced dimerization (CID) initiated by mandipropamid to function as a switch for agrochemical control of gene expression.
Variable Exposure Portable Perfusion Monitor
Methods to Prevent and Treat Diffuse Large and Other B Cell Lymphomas
Professor Ameae Walker from the University of California, Riverside, Professor Srividya Swaminathan from the City of Hope Beckman Research Institute and their colleagues have developed a method for the prevention and treatment of B cell lymphomas. This technology works by systemically inhibiting expression of one form of the set of cell surface molecules that allow cells to respond to prolactin. This highly specific technology suppresses the deleterious downstream effects of prolactin that promote and sustain abnormal B cells. This invention is advantageous compared to existing technologies: all measures in mouse models and analysis of human cells suggest it is nontoxic and therefore will have significantly fewer, if any, side effects. It may also be used together with anti-psychotics that elevate prolactin. Finally, the technology includes a method for screening populations susceptible to development of DLBCL and other B lymphomas for early signs of disease. Antimaia Acts at Three Stages of B Lymphoma Development: 1) Antimaia, a splice modulating oligonucleotide (SMO) that decreases expression of the long form of the prolactin receptor, reduces the number of premalignant cells and the formation of abnormal antibody-producing cells. This also improves the symptomatology of autoimmune disease. 2) Antimaia prevents the conversion of premalignant to overt malignant B cells. 3) Antimaia kills B lymphoma cells. Antimaia works by reducing the number of long and intermediate form prolactin receptors (LF/IF PRLR) without effect on short receptors (SFPRLR). PRL, prolactin; Bcl2, B cell lymphoma 2; Myc, a proto-oncogene.
Multicolor Photonic Pigments From Magnetically Assembled Nanorod Arrays
Magnetochromatic Spheres